Építés alatt – nem éles oldal
Belépés
Visszavonva2. fázis

Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).

A legfontosabb adatok

Ki végzi
Sun Yat-sen University
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Visszavonva
Fázis
2. fázis
Kezdés
2024. jún. 1.
Várható befejezés
2029. ápr. 1.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Aumolertinib
A regiszteradat frissítve
2024. december 10.
Miért állt le
Slow accrual

Ki vehet részt

Életkor
18 év – 75 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 27 feltétel megnézéseKevesebb

Ki vehet részt

  • Target population is high risk NSCLC with resection option for potential cure, as assessed by a faculty surgeon at SYSUCC. This may include clinical stage IB (≥4cm), II and IIIA. Subjects with N3 nodal involvement are not included
  • Subjects should have a detected sensitizing EGFR
  • Written informed consent provided
  • Male and female, aged 18-75 years
  • Able to comply with the required protocol and follow-up procedures, and able to receive oral medications
  • Blood and specimens before and after treatment must be provided
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • Life expectancy ≥12 weeks
  • EGFR activating mutation in exon 19 or 21
  • Adequate hematological function: Absolute neutrophil count (ANC) ≥2.0 x 109/L, and Platelet count ≥100 x 109/L, and Hemoglobin ≥9 g/dL (may be transfused to maintain or exceed this level)
  • Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN), Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x ULN in subjects without liver metastases; ≤ 5 x ULN in subjects with liver metastases
  • Adequate renal function: Serum creatinine ≤ 1.25 x ULN, or ≥ 60 ml/min
  • Female subjects should not be pregnant or breast-feeding

Ki nem vehet részt

  • Had had previous chemotherapy, radiotherapy, or agents directed at the HER axis (e.g. erlotinib, gefitinib, cetuximab, trastuzumab)
  • A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study
  • Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease)
  • Known severe hypersensitivity to aumolertinib or any of the excipients of this product
  • Evidence of clinically active interstitial lung disease
  • Eye inflammation not fully controlled or conditions predisposing the subject to this
  • A serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease
  • History of another malignancy in the last 5 years with the exception of the following: other malignancies cured by surgery alone and having a continuous disease-free interval of 5 years are permitted. Cured basal cell carcinoma of the skin and cured in situ carcinoma of the uterine cervix are permitted
  • Patient who has active serious infection (e.g. pyrexia of or 38.0℃ over)
  • Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
  • Ingredients mixed with small cell lung cancer patients
  • History of neurologic or psychiatric disorders
  • Inability to comply with protocol or study procedures
  • Women who are pregnant or nursing

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Aumolertinib (almonertinib; HS-10296) is a novel third-generation EGFR-TKI showing activity against EGFR-sensitizing mutations and EGFR T790M mutation. The third-generation EGFR-TKI osimertinib has been approved in the adjuvant setting. This study is to studying 3-year aumolertinib as adjuvant therapy to see how well it works in treating patients with resected stage IB-IIIA NSCLC harboring sensitizing EGFR mutations.

A vizsgálat csoportja

  • AumolertinibA vizsgált kezelés

    Aumolertinib 110 mg once daily (110 mg per day) orally for 36 months.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Single-Arm, Open-Lable Study of Adjuvant Aumolertinib for Completely Resected Stage IB-IIIA Non-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.
A regiszteradat frissítve
2024. december 10.